Protective Effects of Clarithromycin, a Lipophilic 14-Membered Macrolide, on Hemolysis Induced by Lysophosphatidylcholine in Human Erythrocytes

Total Page:16

File Type:pdf, Size:1020Kb

Protective Effects of Clarithromycin, a Lipophilic 14-Membered Macrolide, on Hemolysis Induced by Lysophosphatidylcholine in Human Erythrocytes Regular Article Jpn. J. Pharm. Health Care Sci. 38(10) 617―627 (2012) Protective Effects of Clarithromycin, a Lipophilic 14-membered Macrolide, on Hemolysis Induced by Lysophosphatidylcholine in Human Erythrocytes Kuninori Iwayama 1, Yusuke Takashima 1, 4, Ko-ichi Ohtaki 1, 5, Kikutaro Endoh 2, Yoshiko Tampo 3 and Nobumasa Hayase*1 Departments of Pharmacology & Therapeutics 1, Life Sciences 2, and Public & Health 3, Hokkaido Pharmaceutical University School of Pharmacy, Department of Hospital Pharmacy, Oji Sogou Hospital 4, Department of Hospital Pharmacy & Pharmacology, Asahikawa Medical University Hospital 5 Received May 7, 2012 Accepted July 29, 2012 We examined the effects of 8 macrolide antimicrobial agents, including 14-, 15- and 16-membered ring lactone and ketoride derivatives, on hemolysis induced by lysophosphatidylcholine (LPC) in human erythrocytes. LPC induced hemolysis at concentrations above the critical micelle concentration (4 µM). Vitamin E (α-tocopherol), used as a reference drug, attenuated the 50% hemolysis induced by 6 µM LPC when present at concentrations between 1 µM and 100 mM. Clarithromycin significantly attenuated LPC-induced hemolysis at a wider range of concentrations (100 nM to 1 mM), but other macrolides attenuated hemolysis only at high concentrations (100 µM and/or 1 mM). Since vitamin E tends to stabilize membranes due to its high lipophilicity, it appears that the high lipophilicity of clarithromycin is responsible for its protective action against damage induced by LPC. However, rokitamycin was not effective, although it is more lipophilic than clarithromycin, indicating that factors other than high lipophilicity are responsible for the protective effects of macrolide antimicrobial agents against LPC-induced hemolysis. Neither vitamin E nor clarithromycin attenuated hypotonic hemolysis (60 mM NaCl) at concentrations that inhibit LPC-induced hemolysis. On the other hand, both vitamin E and clarithromycin affected LPC micelle formation, suggesting that these drugs directly bind to LPC. We therefore believe that the protective effects of clarithromycin on LPC-induced hemolysis may be related physicochemically to its high lipophilicity and 14-membered ring lactone structure, which help maintain erythrocyte membrane integrity by preventing LPC micelle formation. These drugs likely do not act by a mechanism that protects against osmotic imbalance. Key words ―― anti-inflammatory effect of macrolides, clarithromycin, lysophosphatidylcholine (LPC), hemolysis, lipophilicity necrosis factor alpha and interleukin-8 from bron- Introduction chial epithelial cells. This property affects the mi- Macrolide antimicrobial agents, such as eryth- gration of neutrophils and impairs their genera- romycin, clarithromycin and other 14-, 15-mem- tion of superoxide.5) However, there are limited bered ring macrolides have been shown to be ef- data concerning the direct effect of macrolides on fective for the treatment of chronic airway the cell membrane under inflammatory condi- inammatory disorders. 1-4) The anti-inammatory tions. effect of macrolides may arise from their molecu- The direct cellular effects of macrolides can be lar, biochemical and immunological mechanisms. examined using bronchial epithelial cells. How- For instance, erythromycin inhibits the produc- ever, bronchial epithelial cells have a variety of tion of proinammatory cytokines such as tumor active membrane and cytoplasmic proteins asso- * 7-1 Katuraoka-cho, Otaru-shi, Hokkaido, 047-0264 Japan 617 Jpn. J. Pharm. Health Care Sci. ciated with inflammatory signaling transduction tive action of macrolides against LPC-induced pathways,6) so it is difcult to determine whether cell damage? Human erythrocytes were used as macrolides exert a direct or indirect effect on the model cells, and vitamin E was used as the refer- cell membrane. Human erythrocytes are a conve- ence drug since it is known to attenuate LPC-in- nient cell type in this regard, because they lack a duced hemolysis via a nonspecic mechanism. 13) nucleus and thus nuclear transcriptional regula- tion 7) of the intracellular signaling pathways. Materials and Methods However, although cell membrane damage can be directly detected by hemolysis, it is not obvious 1. Materials how to inict inammatory damage since eryth- Erythromycin stearate, clarithromycin, mideca- rocytes are resistant to oxidative stress,8) which is mycin acetate, kitasamycin and rokitamycin were a primary cause of airway inammation. purchased from Wako Fine Chemicals Co., Ltd. Lysophosphatidylcholine (LPC) is a bioactive (Osaka, Japan). Telithromycin was obtained from phospholipid that accumulates significantly in Roussel Uclaf S.A. (Romainville Cedex, France), bronchoalveolar lavage fluid during airway in- and cethromycin was kindly donated by Abbott ammation and inicts inammation-like damage Laboratories, Inc. (Abbott Park, IL, USA). on erythrocytes.9, 10) It has therefore been assumed Azithromycin hydrate, vitamin E (tocopherol ace- that LPC plays a role in inflammation-induced tate), and LPC (palmitoyl C16:0) were pur- cell damage. chased from Sigma Chemical Co. (St Louis, MO, Several reports have discussed the effect of USA), and 8-anilino-1-naphthalenesulphonic acid macrolides on LPC-induced cell damage. Feld- was obtained from Tokyo Kasei Kogyo Co., Ltd. man et al. 11) demonstrated that roxithromycin, (Tokyo, Japan). Other chemicals were purchased clarithromycin and azithromycin attenuate LPC- from Wako Fine Chemicals Co., Ltd. (Osaka, Japan). induced damage to isolated human ciliated epi- LPC was dissolved in distilled water to achieve thelium, indicating that these macrolides exert di- the desired concentrations and then allowed to rect cytoprotective action against LPC-induced stand at 4 °C for at least 12 hours. Clarithromycin damage, which may contribute to their anti-in- was dissolved in dimethylsulfoxide (DMSO) and flammatory properties against airway inflamma- then diluted with distilled water to a nal DMSO tory disorders. Nevertheless, it is uncertain concentration of 0.0002-0.02%. The other macro- whether the cytoprotective effects of these macro- lides and vitamin E were dissolved in ethanol and lides on epithelial cells are due to their direct ac- then diluted with distilled water to a nal ethanol tion, because active membrane and cytoplasm concentration of 0.0002-0.02%. Other drugs were proteins are associated with the inflammatory dissolved in distilled water. All drug solutions process in human ciliated epithelium.12) tested were prepared immediately before use. The present study was designed to answer two DMSO and ethanol did not produce hemolysis at questions: 1) do macrolide antimicrobial agents the concentrations used in the present study (data exert a direct cytoprotective action against LPC- not shown). induced cell damage? and 2) are differences in 2. Blood sampling chemical structure responsible for the cytoprotec- Human blood was supplied the Hokkaido Red 618 Vol.38,No.10(2012) Cross Blood Center (Sapporo, Japan); the blood bance of hemoglobin released into the supernatant was drawn from healthy donors several days be- using a Hitachi model 200-10 spectrophotometer fore use. Each blood sample was washed four at a wavelength of 543 nm. The maximum hemo- times with isotonic buffer (10 mM phosphate buf- lysis obtained with distilled water was taken as fer containing 154 mM NaCl, pH 7.4) to remove 100%, and the minimum (spontaneous) hemoly- the buffy coat and plasma to yield a 40% (V/V) sis obtained in the isotonic buffer was taken as erythrocyte suspension. 0%. The preliminary experiments revealed that experimental conditions producing around 50% 3. Hemolysis induced by LPC and hypo- hemolysis, obtained using 6 µM LPC or 60 mM tonic solution NaCl (Fig. 1), were suitable for evaluating the ef- Preliminary experiments were performed to de- fects of drugs on erythrocytes. We therefore used termine the extent of hemolysis in response to 6 µM LPC and 60 mM NaCl for LPC- and NaCl- different concentrations of LPC or NaCl. The induced hemolysis, respectively. 40% erythrocyte suspension (1 mL) was diluted with isotonic buffer solution (5 mL) and incubat- 4. Effects of macrolides and vitamin E on ed for 30 min at 37 °C. The diluted erythrocyte LPC-induced hemolysis suspension (200 µL) was mixed with isotonic or The effects of drugs (8 macrolides and vitamin hypotonic buffer (5 mL) containing different con- E) on LPC-induced hemolysis were examined. centrations of LPC (2-20 µM) or NaCl (45-75 First, the 40% erythrocyte suspension (200 µL) mM). This resulting mixture (sample) contained was mixed with isotonic buffer (1 mL) containing about 0.26% erythrocytes. Each sample was in- each of the drugs individually at various concen- cubated for 30 min at 37 °C and centrifuged at trations, and incubated for 30 min at 37 °C. Sam- 1300×g for 5 min. After centrifugation, the ex- ples containing one of the drugs and LPC were tent of hemolysis was determined from the absor- then prepared to measure the extent of hemolysis. Fig. 1 Extent of hemolysis in response to different concentrations of LPC (A) or NaCl (B) A:Erythrocytes and LPC were incubated in isotonic buffer (10 mM phosphate buffer containing 145 mM NaCl; pH 7.4), and B:erythrocytes were incubated in hypotonic buffer (10 mM phosphate buffer containing 45 to 75 mM NaCl; pH 7.4) for 30 min at 37 °C. Each point is the mean±SEM of five experiments. 619 Jpn. J. Pharm. Health Care Sci. The concentrations of the drugs in the isotonic 7. Statistical analysis buffer solutions were 10 nM, 100 nM, 1 µM, 10 µM, 100 µM or 1 mM, and the concentration of All values are expressed as the means±SEM. LPC was 6 µM. Each sample was further incubat- Statistical analysis was performed using ANOVA ed for 30 min at 37 °C and then centrifuged at followed by the post hoc Dunnett’s t-test for com- 1300×g for 5 min. The extent of hemolysis was paring the control group with each of the drug- measured as described above. Neither the macro- treated groups. A probability value of P < 0.05 lides nor vitamin E interfered with the measure- was considered statistically signicant. ment of hemolysis.
Recommended publications
  • Pharmaceutical Microbiology Table of Contents
    TM Pharmaceutical Microbiology Table of Contents Pharmaceutical Microbiology ������������������������������������������������������������������������������������������������������������������������ 1 Strains specified by official microbial assays ������������������������������������������������������������������������������������������������ 2 United States Pharmacopeia (USP) �������������������������������������������������������������������������������������������������������������������������������������������2 European Pharmacopeia (EP) Edition 8�1 ���������������������������������������������������������������������������������������������������������������������������������5 Japanese Pharmacopeia (JP) ������������������������������������������������������������������������������������������������������������������������������������������������������7 Strains listed by genus and species �������������������������������������������������������������������������������������������������������������10 ATCC provides research and development tools and reagents as well as related biological material management services, consistent with its mission: to acquire, authenticate, preserve, develop, and distribute standard reference THE ESSENTIALS microorganisms, cell lines, and related materials for research in the life sciences� OF LIFE SCIENCE For over 85 years, ATCC has been a leading authenticate and further develop products provider of high-quality biological materials and services essential to the needs of basic and standards to the life
    [Show full text]
  • Nature Nurtures the Design of New Semi-Synthetic Macrolide Antibiotics
    The Journal of Antibiotics (2017) 70, 527–533 OPEN Official journal of the Japan Antibiotics Research Association www.nature.com/ja REVIEW ARTICLE Nature nurtures the design of new semi-synthetic macrolide antibiotics Prabhavathi Fernandes, Evan Martens and David Pereira Erythromycin and its analogs are used to treat respiratory tract and other infections. The broad use of these antibiotics during the last 5 decades has led to resistance that can range from 20% to over 70% in certain parts of the world. Efforts to find macrolides that were active against macrolide-resistant strains led to the development of erythromycin analogs with alkyl-aryl side chains that mimicked the sugar side chain of 16-membered macrolides, such as tylosin. Further modifications were made to improve the potency of these molecules by removal of the cladinose sugar to obtain a smaller molecule, a modification that was learned from an older macrolide, pikromycin. A keto group was introduced after removal of the cladinose sugar to make the new ketolide subclass. Only one ketolide, telithromycin, received marketing authorization but because of severe adverse events, it is no longer widely used. Failure to identify the structure-relationship responsible for this clinical toxicity led to discontinuation of many ketolides that were in development. One that did complete clinical development, cethromycin, did not meet clinical efficacy criteria and therefore did not receive marketing approval. Work on developing new macrolides was re-initiated after showing that inhibition of nicotinic acetylcholine receptors by the imidazolyl-pyridine moiety on the side chain of telithromycin was likely responsible for the severe adverse events.
    [Show full text]
  • WO 2016/120258 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2016/120258 A l 4 August 2016 (04.08.2016) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/00 (2006.01) A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/20 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP20 16/05 1545 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 26 January 2016 (26.01 .2016) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 264/MUM/2015 27 January 2015 (27.01 .2015) IN kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: JANSSEN PHARMACEUTICA NV TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).
    [Show full text]
  • US 2002/0071822 A1 Uhrich (43) Pub
    US 20020071822A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0071822 A1 Uhrich (43) Pub. Date: Jun. 13, 2002 (54) THERAPEUTIC POLYESTERS AND provisional application No. 60/261,337, filed on Jan. POLYAMIDES 12, 2001. (76) Inventor: Kathryn E. Uhrich, Hoboken, NJ (US) Publication Classification Correspondence Address: (51) Int. Cl." ..................... A61K 31/785; A61K 31/765; SCHWEGMAN, LUNDBERG, WOESSNER & C08G 63/685; CO8G 63/688 KLUTH, PA. (52) U.S. Cl. ....................... 424/78.37; 528/288; 528/293 P.O. BOX 2938 MINNEAPOLIS, MN 55402 (US) (57) ABSTRACT (21) Appl. No.: 09/917,194 Polymers (i.e. polyesters, polyamides, and polythioesters or (22) Filed: Jul. 27, 2001 a mixture thereof) which degrade hydrolytically into bio logically active compounds are provided. Methods of pro Related U.S. Application Data ducing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to (63) Non-provisional of provisional application No. deliver biologically active compounds to a host are also 60/220,707, filed on Jul. 27, 2000. Non-provisional of provided. US 2002/0071822 A1 Jun. 13, 2002 THERAPEUTIC POLYESTERS AND POLYAMDES 0012. The invention also provides processes and inter mediates disclosed herein that are useful for preparing a PRIORITY OF INVENTION polymer of the invention. 0001. This application claims priority from U.S. Provi DETAILED DESCRIPTION OF THE sional Application No. 60/220,707, filed Jul. 27, 2000 and INVENTION U.S. Provisional Application No. 60/261,337, filed Dec. 1, 2001, which are incorporated herein by reference. 0013 Definitions 0014. The following definitions are used, unless other BACKGROUND OF THE INVENTION wise described: halo is fluoro, chloro, bromo, or iodo.
    [Show full text]
  • Effects of Chlortetracycline and Copper Supplementation on Levels of Antimicrobial Resistance in the Feces of Weaned Pigs
    EFFECTS OF CHLORTETRACYCLINE AND COPPER SUPPLEMENTATION ON LEVELS OF ANTIMICROBIAL RESISTANCE IN THE FECES OF WEANED PIGS by GETAHUN EJETA AGGA DVM, Addis Ababa University, 2003 MSc, Utrecht University, 2008 AN ABSTRACT OF A DISSERTATION submitted in partial fulfillment of the requirements for the degree DOCTOR OF PHILOSOPHY Department of Diagnostic Medicine/Pathobiology College of Veterinary Medicine KANSAS STATE UNIVERSITY Manhattan, Kansas 2013 Abstract The use of antibiotics in food animals is of major concern as a purported cause of antimicrobial resistance (AMR) in human pathogens; as a result, alternatives to in-feed antibiotics such as heavy metals have been proposed. The effect of copper and CTC supplementation in weaned pigs on AMR in the gut microbiota was evaluated. Four treatment groups: control, copper, chlortetracycline (CTC), and copper plus CTC were randomly allocated to 32 pens with five pigs per pen. Fecal samples (n = 576) were collected weekly from three pigs per pen over six weeks and two Escherichia coli isolates per sample were tested phenotypically for antimicrobial and copper susceptibilities and genotypically for the presence of tetracycline (tet), copper (pcoD) and ceftiofur (blaCMY-2) resistance genes. CTC-supplementation significantly increased tetracycline resistance and susceptibility to copper when compared with the control group. Copper supplementation decreased resistance to most of the antibiotics, including cephalosporins, over all treatment periods. However, copper supplementation did not affect minimum inhibitory concentrations of copper or detection of pcoD. While tetA and blaCMY-2 genes were associated with a higher multi-drug resistance (MDR), tetB and pcoD were associated with lower MDR. Supplementations of CTC or copper alone were associated with increased tetB prevalence; however, their combination was paradoxically associated with reduced prevalence.
    [Show full text]
  • Surveillance of Antimicrobial Consumption in Europe 2013-2014 SURVEILLANCE REPORT
    SURVEILLANCE REPORT SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe in Europe consumption of antimicrobial Surveillance Surveillance of antimicrobial consumption in Europe 2013-2014 2012 www.ecdc.europa.eu ECDC SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe 2013–2014 This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Klaus Weist. Contributing authors Klaus Weist, Arno Muller, Ana Hoxha, Vera Vlahović-Palčevski, Christelle Elias, Dominique Monnet and Ole Heuer. Data analysis: Klaus Weist, Arno Muller and Ana Hoxha. Acknowledgements The authors would like to thank the ESAC-Net Disease Network Coordination Committee members (Marcel Bruch, Philippe Cavalié, Herman Goossens, Jenny Hellman, Susan Hopkins, Stephanie Natsch, Anna Olczak-Pienkowska, Ajay Oza, Arjana Tambić Andrasevic, Peter Zarb) and observers (Jane Robertson, Arno Muller, Mike Sharland, Theo Verheij) for providing valuable comments and scientific advice during the production of the report. All ESAC-Net participants and National Coordinators are acknowledged for providing data and valuable comments on this report. The authors also acknowledge Gaetan Guyodo, Catalin Albu and Anna Renau-Rosell for managing the data and providing technical support to the participating countries. Suggested citation: European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2013‒2014. Stockholm: ECDC; 2018. Stockholm, May 2018 ISBN 978-92-9498-187-5 ISSN 2315-0955
    [Show full text]
  • T Genetic Name of Midecamycin Acetate(MOM)
    1086 THE JOURNAL OF ANTIBIOTICS AUG.198Z SYNERGISTIC EFFECTS OF A MACROLiDE AND A CELL WALL-AFFECTING ANTIBIOTIC ON PSEUDOMONAS AERUGINOSA IN VITRO AND IN VIVO 3.INCORPORATION OF[14C]MIDECAMYCIN ACETATE(MOM)† INTO P.AERUGINOSA PRETREATED WITH CELL WALL-AFFECTING. ANTIBIOTICS TAKAo KAsAI,*TosHlo ToMITA, SHIRo KANEGAsAKI and J, YuzuRu HoMMA** Department of Bacteriology,Institute of Medical Science, Universityof Tokyo, Shiroganedai, Minato-ku, Tokyo lO8, Japan (Received for publicatioll April l7,1982) Thc occurrence inρ 一lactam treated patiellts of unstable L-forms of Pseudomonas aeruginosa hlscnsitivc to various antibiotics and synergistic effect ofcombined action of celi wa11-affecting antibiotics and macrolide on Pseudomonas infection led us to examine thc effects of macrolidc on P.aeruginosa pretreated with cell wail-affbcting antibiotics. The effects of macrolide antibiotics such as midecamycin acetate(MOM)on P. aeruginosa was investigated, a rapid killing effect by MOM was lloted after treatmellt wkh suboptimal doses of ce11 wa11-affecting antibiotics such as polymyxin B, carbenicillin, dibekacill or fosfomycin. IIlcorporation of [1.4C]MOM lllto intact P.aeruginosa cells was not significant, but was apparent into L-form cells or cells pretreated wiIh cell wall-affecting antibiotics, The incor- porated radioactlvity was found in thc 70 S ribosome fractio11, binding with the 50 S subunits of ribosome in both cases, These results indicate tllat under certain conditions a macrolidc antibiotic can emer the P.aeruginosa cell, YAMAMoTo and HoMMA1)reported isolating unstable L-forms from clinical specimens of patients with chronic respiratory tract infection and cow mastitis due to P.aeruginosa who were undergoingβ 一 l actanl antibiotic therapy.
    [Show full text]
  • Antibiotics and Antibiotic Resistance
    This is a free sample of content from Antibiotics and Antibiotic Resistance. Click here for more information on how to buy the book. Index A Antifolates. See also specific drugs AAC(60)-Ib-cr, 185 novel compounds, 378–379 ACHN-975 overview, 373–374 clinical studies, 163–164 resistance mechanisms medicinal chemistry, 166 sulfamethoxazole, 378 structure, 162 trimethoprim, 374–378 AcrAB-TolC, 180 Apramycin, structure, 230 AcrD, 236 Arbekacin, 237–238 AdeRS, 257 Avibactam, structure, 38 AFN-1252 Azithromycin mechanism of action, 148, 153 resistance, 291, 295 resistance, 153 structure, 272 structure, 149 Aztreonam, structure, 36 AIM-1, 74 Amicoumacin A, 222 Amikacin B indications, 240 BaeSR, 257 structure, 230 BAL30072, 36 synthesis, 4 BB-78495, 162 Aminoglycosides. See also specific drugs BC-3205, 341, 344 historical perspective, 229–230 BC-7013, 341, 344 indications, 239–241 b-Lactamase. See also specific enzymes mechanism of action, 232 classification novel drugs, 237 class A, 67–71 pharmacodynamics, 238–239 class B, 69–74 pharmacokinetics, 238–239 class C, 69, 74 resistance mechanisms class D, 70, 74–77 aminoglycoside-modifying enzymes evolution of antibiotic resistance, 4 acetyltransferases, 233–235 historical perspective, 67 nucleotidyltransferases, 235 inhibitors phosphotransferases, 235 overview, 37–39 efflux-mediated resistance, 236 structures, 38 molecular epidemiology, 236–237 nomenclature, 67 overview, 17, 233 b-Lactams. See also specific classes and antibiotics ribosomal RNA modifications, 235–236 Enterococcus faecium–resistancemechanisms,
    [Show full text]
  • Miconazole Nitrate Add Methanol to Make Exactly 20 Ml, and Use This Solution As the Standard Solution
    JP XV O‹cial Monographs / Micronomicin Sulfate 893 sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 20 mL, pipet 1 mL of this solution, Miconazole Nitrate add methanol to make exactly 20 mL, and use this solution as the standard solution. Perform the test with these solutions ミコナゾール硝酸塩 as directed under Thin-layer Chromatography <2.03>. Spot 50 mL each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of n-hexane, chloroform, methanol and ammonia solution (28) (60:30:10:1) to a distance of about 12 cm, and air-dry the plate. Allow the plate in iodine vapor for 20 minutes: the spots other than the principal spot from the sample solution are not more intense than the spot from the standard solution. Loss on drying <2.41> Not more than 0.5z (1 g, in vacuum, C18H14Cl4N2O.HNO3: 479.14 silica gel, 609C, 3 hours). 1-[(2RS)-2-(2,4-Dichlorobenzyloxy)-2-(2,4- Residue on ignition <2.44> Not more than 0.1z (1 g). dichlorophenyl)ethyl]-1H-imidazole mononitrate [22832-87-7 ] Assay Weigh accurately about 0.35 g of Miconazole Ni- trate, previously dried, dissolve in 50 mL of acetic acid (100) Miconazole Nitrate, when dried, contains not less by warming, cool, and titrate <2.50> with 0.1 molWL perchlor- than 98.5z of C18H14Cl4N2O.HNO3. ic acid VS (potentiometric titration). Perform a blank deter- mination, and make any necessary correction. Description Miconazole Nitrate occurs as a white crystal- line powder.
    [Show full text]
  • Zebrafish As a Screening Model to Study the Single and Joint Effects Of
    pharmaceuticals Review Zebrafish as a Screening Model to Study the Single and Joint Effects of Antibiotics † Roxana Jijie 1,2,*,‡, Gabriela Mihalache 3,4,‡, Ioana-Miruna Balmus 2, Stefan-Adrian Strungaru 2 , Emanuel Stefan Baltag 1 , Alin Ciobica 5, Mircea Nicoara 5,6 and Caterina Faggio 7,* 1 Marine Biological Station “Prof. dr. I. Borcea”, “Alexandru Ioan Cuza” University of Iasi, Nicolae Titulescu Street, No. 163, 9007018 Agigea, Romania; [email protected] 2 Department of Exact and Natural Sciences, Institute of Interdisciplinary Research, “Alexandru Ioan Cuza” University of Iasi, 11 Carol I, 700506 Iasi, Romania; [email protected] (I.-M.B.); [email protected] (S.-A.S.) 3 Integrated Center of Environmental Science Studies in the North Eastern Region (CERNESIM), “Alexandru Ioan Cuza” University of Iasi, 11 Carol I, 700506 Iasi, Romania; [email protected] 4 Department of Horticultural Technologies, “Ion Ionescu de la Brad” University of Agricultural Sciences and Veterinary Medicine, 700440 Iasi, Romania 5 Department of Biology, Faculty of Biology, “Alexandru Ioan Cuza” University of Iasi, B-dul Carol I, 700505 Iasi, Romania; [email protected] (A.C.); [email protected] (M.N.) 6 Doctoral School of Geosciences, Faculty of Geography-Geology, “Alexandru Ioan Cuza” University of Iasi, B-dul Carol I, 700505 Iasi, Romania 7 Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale F. Stagno, d’Alcontres, 31 98166 S. Agata-Messina, Italy * Correspondence: [email protected] (R.J.); [email protected] (C.F.) † This paper is dedicated to the memory of Stefan-Adrian Strungaru, colleague, researcher and friend, who prematurely passed away in April 2021.
    [Show full text]
  • Development of Novel Antibiotic Classes
    60 years ago… The changes in antibiotic research as shown by patent publications Development of Novel Antibiotic Classes 1930 1940 1950 1960 1970 1980 1990 2000 2003 Daptomycin 1999 Linezolid 1962 Quinolones 1962 Streptogramins 1958 Glycopeptides 1952 Macrolides 1950 Aminoglycosides 1949 Chloramphenicol 1949 Tetracyclines 1940 Beta-Lactams 1936 Sulfonamides Harald Labischinski Products in the Pipeline Product Class Main Segment Status ABT 492 Quinolone Community Ph II DK507k Quinolone Community Ph I Daptomycin Lipopeptide Hospital Reg. Oritavancin Glycopeptide Hospital Ph III Dalbavancin Glycopeptide Hospital Ph III Tigecycline Glycylcycline Hospital Ph III AR 100 Trimethoprime Hospital Ph II BAL 9141 Cephalosporin Hospital Ph II BB-83698 PDF-inhibitor Community Ph I CS-023 Carbapenem Hospital Ph II Until 2008 very few antibiotics will reach the market ! Harald Labischinski 60 years ago… 1942 Gardner and Chain discover a substance with antibacterial activity, produced by a strain of Proactinomyces (later Streptomyces gardneri), which they name proactinomycin A. Macrolide structure • Macrolides are lipophilic molecules with a characteristic central lactone ring bearing 12 to 17 atoms, few if any double bonds and no nitrogen athoms (until the advent of the azalides). • Several amino and/or neutral sugars can bind to the lactone ring. MACROLIDE ANTIBIOTICS 12-membered-ring 14-membered-ring 15-membered-ring 16-membered-ring 17-membered-ring Methymycin Natural Semi-synthetic Azithromycin Natural Semi-synthetic Lankacidin Neomethymycin compounds derivatives compounds derivatives complex YC-17 Litorin Erythromycin A to F Roxithromycin Josamycin Rokitamycin Oleandomycin Dirithromycin Kitasamycin Miokamycin Sporeamicin Flurithromycin Spiramycin Clarithromycin Midecamycin • The macrolides narrow the entrance of the tunnel through which the nascent polypeptide chain is extruded from the ribosome.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]